Physician profile
John A Stevenson
NPI 1205820966
$3,222.11
in general payments reported to CMS, 2019-2025
21 companies · $826 in 2025
The $826 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $229 · 2020: $90.67 · 2021: $197 · 2022: $446 · 2023: $766 · 2024: $667 · 2025: $826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,239 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,239.36 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $904.00 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $553.23 | 2019-2025 | Jynarque, Voyxact |
| Astrazeneca Pharmaceuticals LP | $342.07 | 2019-2025 | Farxiga, Lokelma |
| Travere Therapeutics, INC. | $261.33 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $234.30 | 2023-2025 | Jardiance |
| Amgen INC. | $166.00 | 2019-2022 | |
| Aurinia Pharma U.S., INC. | $125.89 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $123.51 | 2024-2025 | |
| Genzyme Corporation | $123.03 | 2025 | |
| Vifor Pharma, INC. | $106.54 | 2022-2025 | Veltassa |
| Fresenius USA Marketing, INC. | $62.82 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $36.74 | 2024 | Purified Cortrophin Gel |
| Pfizer INC. | $33.86 | 2019-2023 | |
| Ardelyx, INC. | $22.46 | 2024 | Ibsrela |
| Daiichi Sankyo INC. | $22.37 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $19.85 | 2021 | |
| Alexion Pharmaceuticals, INC. | $18.90 | 2022 | |
| Calliditas Therapeutics US INC. | $17.37 | 2025 | Tarpeyo |
| Opko Pharmaceuticals, LLC | $17.15 | 2021 | |
| Baxter Healthcare | $16.10 | 2019 | |
| Horizon Therapeutics Plc | $14.59 | 2023 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Stevenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.